Skip to main content

Table 3 FBG levels of patients with T2DM at 6 and 12 months after MSC therapy

From: Efficacy of mesenchymal stem cell transplantation therapy for type 1 and type 2 diabetes mellitus: a meta-analysis

Follow-up (months) Test for heterogeneity Analysis model Test for overall effect WMD or SMD 95% CI
I2 (%) P Z P
6 58 0.09 Random 0.73 0.46 −2.8 (−1.02, 0.47)
12 84 0.01 Random 0.72 0.47 0.54 (−0.93, 2.00)
  1. Abbreviations: FBG fasting blood glucose, T2DM type 2 diabetes, MSCs mesenchymal stem cells, WMD weighted mean difference, SMD standard mean difference